Introduction {#s1}
============

Osteoporosis affects over 200 million adults worldwide, and associated fractures are costly, with high morbidity and mortality and limited treatment options ([@c31]). Because bone accrues during childhood and adolescence and is maximized by early adulthood ([@c15]), identifying and remediating factors that lead to low bone accrual in childhood is a critical component of osteoporosis prevention efforts. However, our understanding of the role of environmental factors on childhood bone accrual is limited.

Per- and polyfluoroalkyl substances (PFASs), ubiquitous environmental contaminants added to food packaging, clothing, furniture, and carpets to make the products nonstick and stain repellant ([@c24]), are universally detectable in the general U.S. population, including children ([@c4]; [@c45]).

PFASs may influence areal bone mineral density (aBMD) through several mechanisms. PFASs activate the nuclear peroxisome proliferator--activated receptor gamma ($\text{PPAR}\gamma$), which suppresses the osteoblast lineage of mesenchymal stem cells ([@c44]). PFASs may also reduce BMD by acting as androgen receptor antagonists ([@c7]; [@c21]), inhibiting steroidogenic enzyme activity on the androgen secretion pathway ([@c47]) or by directly intercalating into bone ([@c2]; [@c22]; [@c30]). Consistent with these mechanistic data, two epidemiologic studies in U.S. adults reported higher PFAS serum concentrations to be associated with lower aBMD ([@c18]; [@c23]), and in a pilot cross-sectional study of 48 obese children, higher PFAS plasma concentrations were associated with lower aBMD measured by calcaneal quantitative ultrasound ([@c19]).

The extent to which different PFASs may affect aBMD in children is not well characterized. Based on limited existing data suggesting a contemporaneous inverse association between PFAS exposure and aBMD, we set out to test the hypothesis that higher plasma PFAS concentrations would be cross-sectionally associated with lower aBMD *z*-score at midchildhood in a large Boston-area cohort.

Methods {#s2}
=======

Study Population and Design {#s2.1}
---------------------------

Between 1999 and 2002, we recruited pregnant women to Project Viva, a longitudinal cohort study of prenatal exposures and child health, during their first prenatal visit at Atrius Harvard Vanguard Medical Associates, a multispecialty group practice in eastern Massachusetts ([@c29]). Of 2,128 mother--infant pairs, 1,116 (54%) children had a follow-up research visit in midchildhood (age range, 6--10 y; median, 7.7 y). At the midchildhood visit, 653 (59%) of these children had PFAS concentrations measured in plasma, and 576 children from this population had aBMD measured by dual-energy X-ray absorptiometry (DXA) and thus were included in the present analysis. Among participants who attended the midchildhood visit, participants who were included in the statistical analysis were less likely to be white compared with excluded participants (57% vs. 70%). Although included participants' mothers were less likely to have graduated from college (64% vs. 72%), they were more likely to belong to households with high income (total annual income $> \$ 70,000$) compared with participants who were excluded (80% vs. 68%) (see Table S1).

The institutional review boards of participating institutions approved this analysis. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory did not constitute engagement in human subjects research. All mothers provided written informed consent for their child's participation.

Exposure and Outcome Measurements {#s2.2}
---------------------------------

We measured several PFASs in plasma collected in midchildhood as previously described ([@c36]). Staff at the Division of Laboratory Sciences at the CDC quantified PFASs using online solid-phase extraction with isotope dilution high-performance liquid chromatography--mass spectrometry. The limit of detection (LOD) was $0.1\text{ \ ng}/{mL}$ for all PFASs; we replaced values below the LOD with the $\text{LOD}/\left. \sqrt{}2 \right.$. We summed the concentrations of the isomers of perfluorooctanoic acid (PFOA) \[i.e., n-PFOA and the sum of perfluoromethylheptanoates and perfluorodimethylhexanoates (Sb-PFOA)\] to obtain total PFOA. We summed the concentrations of the isomers of perfluorooctanesulfonic acid (PFOS) \[i.e., n-PFOS, sum of perfluoromethylheptane sulfonates (Sm-PFOS), and sum of perfluorodimethylhexane sulfonates (Sm2-PFOS)\] to obtain total PFOS. We decided *a priori* to only consider PFASs with detectable concentrations in $> 60\%$ of samples for the current analysis. The PFASs that met this threshold were n-PFOA, n-PFOS, Sm-PFOS, total PFOA, total PFOS, perfluorodecanoate (PFDA, previously abbreviated as PFDeA), perfluorohexane sulfonate (PFHxS), 2-(N-methyl-perfluorooctane sulfonamide) acetate (MeFOSAA, previously abbreviated as MePFOSA-AcOH), and perfluorononanoate (PFNA).

We measured total-body (excluding the skull) aBMD and bone mineral content (BMC) in midchildhood via a total-body DXA scan (Discovery A model; Hologic Inc.). In order to avoid variation in aBMD measures between DXA instruments ([@c3]), we used the same DXA scanner for all participants and calibrated it daily with a standard phantom from the manufacturer to assess for machine drift. We excluded the skull in the measurements because the skull comprises a large proportion of the skeleton in growing children and is not responsive to physical activity or other environmental influences ([@c10]). Total body less head measurements are also recommended for clinical pediatric skeletal assessments ([@c14]). Intrarater reliability on a subset of measurements was high $\text{Intraclass\ correlation}\left( \text{ICC} \right) > 0.91$. We analyzed data with Hologic software (version 12.6) using the pediatric setting and used U.S. national reference data to derive age-, sex-, race-, and height-adjusted aBMD and BMC *z*-scores ([@c46]).

Covariates {#s2.3}
----------

We administered questionnaires to collect data on maternal education, parity, smoking habits during pregnancy and child secondhand smoke exposure, breastfeeding duration, annual household income, and race/ethnicity. At the midchildhood visit, we used a PrimeScreen questionnaire to collect information on the child's soda and dairy (milk, yogurt, cheese, butter, and ice cream) intake in servings per day over the past month ([@c32]). In a subset of children ($n = 546$), we measured serum 25-hydroxyvitamin D \[25(OH)D\] using isotope dilution liquid chromatography--tandem mass spectrometry ([@c1]; [@c37]). Based on home address recorded at the midchildhood visit, we obtained median annual household income for the child's residential census tract from U.S. Census data ([@c40]).

Statistical Analyses {#s2.4}
--------------------

We first ran single-PFAS linear regression models to examine independent associations between each PFAS and aBMD *z*-score. Next, we ran a multi-PFAS linear regression model to examine associations between each PFAS and aBMD *z*-score, independent of the other PFASs. Finally, we examined the association between the PFAS mixture and aBMD *z*-score via weighted quantile sum (WQS) regression. The distributions of all plasma PFAS concentrations were right skewed. To evaluate nonlinearity, we fit penalized spline generalized additive models of the associations of individual PFASs with aBMD *z*-scores. Associations were linear when PFAS plasma concentrations were $\log_{2}$ transformed. We therefore used $\log_{2}$-transformed PFAS plasma concentrations in our linear regression analyses and in developing a composite weighted index in the WQS analysis.

In all models, we accounted for potential positive or negative confounders of the association between PFAS plasma concentration ([@c36]) and aBMD *z*-score ([@c35]). We evaluated linearity of the relationship between each continuous covariate and the outcome using penalized spline generalized additive models, and we categorized covariates that were nonlinearly associated with aBMD *z*-score. The covariates that we included in our final models were maternal age at enrollment (years), maternal education (with or without college degree), individual household income ($< \$ 40,000$, $\$ 40,000–70,000$, $> \$ 70,000$), census tract median household income ($< \$ 30,000$, $\$ 30,000–60,000$, $\$ 60,000–100,000$, $> \$ 100,000$), child age (years), sex (dichotomous), race/ethnicity (white, black, Asian, Hispanic, other), dairy intake (servings per week), physical activity (hours per week), and year of blood draw for PFAS measurement (2007--2010). We included census tract median household income in addition to individual household income data because we have previously shown census tract median household income to be more strongly associated with PFAS concentrations ([@c17]). Collinearity between the income variables did not impact the results, based on variance inflation factors $\left( \text{VIFs} \right) < 10$ in the final models ($\text{VIF} < \, 1.5$ for each category of census tract median household income, and $\text{VIF} < \, 1.9$ for each category of individual household income).

We considered but did not include the following variables (see Table S2 for descriptive data): breastfeeding duration, soda intake, secondhand smoke exposure, and 25(OH)D plasma concentration. Figure S1 demonstrates that these variables did not confound the PFAS--aBMD association (i.e., estimate for the primary exposure changed by $< 10\%$). We did not consider pubertal status or body mass index (BMI) *z*-score/adiposity, as these variables may be on the causal pathway between PFAS exposure and aBMD *z*-score ([@c13]; [@c25]; [@c11]), and inclusion in the analysis could introduce collider bias ([@c8]). We substituted maternal race/ethnicity for the 10% of children in the cohort who were missing data on race/ethnicity. We performed complete case analyses. Among participants with available exposure/outcome data, 92.2% had information on all covariates and thus were included in our models.

In our single- and multi-PFAS linear regression models, we examined associations between the following individual PFASs and aBMD *z*-score: total PFOA, total PFOS, PFDA, PFHxS, MeFOSAA, and PFNA. Next, we used WQS to estimate the association between the PFAS mixture and aBMD *z*-score. WQS assigns each PFAS within the mixture a weight that reflects the strength of that PFAS--outcome association. However, the weight of each PFAS is also affected by the collinearity between that PFAS and other PFASs in the mixture, such that a given PFAS will have a lower weight if it is highly correlated with another PFAS in the mixture. In this case, the sum of the two weights reflect the contribution of the correlated components to the overall mixture effect. ([@c5]).Our WQS model takes the form $Y_{i} = \beta_{0} + \beta_{1}\sum\limits_{j}w_{j}d_{ij} + \beta_{2}X_{i} + \varepsilon_{i}$, where $d_{ij}$ is the decile corresponding to the *j*th exposure for the *i*th person, $w_{j}$ is a weight for the *j*th exposure estimated by 500 bootstraps, and $\beta_{1}$ represents the overall effect of the mixture. We constrained weights $w_{j}$ to sum to 1.0 so that all mixture components could be incorporated into a single effect estimate, we constrained $\beta$ to be negative based on findings in individual PFAS models, and we scaled $\beta_{1}$ by interquartile range (IQR) of the WQS index to improve interpretability.

We assessed the robustness of our findings through multiple sensitivity analyses of the single-PFAS linear regression models. To control for prenatal PFAS exposure, we adjusted final models for $\log_{2}$-transformed maternal PFAS concentration in early pregnancy, measured at a median of 10 wk gestation (except for the model of PFDA, as PFDA plasma concentrations were below the LOD for 44% of maternal samples). We also examined the associations of PFOS and PFOA isomers with $> 60\%$ detectable concentrations (i.e., n-PFOA, n-PFOS, Sm-PFOS) with aBMD *z*-score. Additionally, we evaluated the association between plasma PFAS concentrations and BMC *z*-score. While BMC does not track as strongly as BMD with its *z*-score at skeletal maturity ([@c43]), it incorporates bone mass (g) and, compared with BMD, has the advantage of accounting for bone thickness and may be less susceptible to confounding due to bone size ([@c10]). Finally, we assessed for effect modification by child sex via an interaction term and stratification.

For penalized spline generalized additive models and WQS regression, we used R (version 3.3.2; R Development Core Team), and for all other analyses, SAS (version 9.4; SAS Institute Inc.).

Results {#s3}
=======

Population Characteristics {#s3.1}
--------------------------

Children were \[$\text{mean} \pm \text{standard\ deviation\  }\left( \text{SD} \right)$\] $7.9 \pm 0.8\;\text{years}$ of age at the midchildhood visit, and ($\text{mean} \pm \text{SD}$) aBMD *z*-score was $- 0.86 \pm 0.77$. Forty-nine percent of children were female, 57% were white, and mothers of 64% were college graduates at the time of cohort enrollment. Children with the highest PFOA concentrations were more likely to be younger, white, live in a census tract with higher median household income, and to have greater dairy intake and earlier blood collection. Mothers of children with the highest PFOA concentrations were more likely to be older and college graduates ([Table 1](#t1){ref-type="table"}).

###### 

Participant characteristics overall ($n = 576$) and by quartiles of total perfluorooctanoic acid (PFOA) plasma concentration in midchildhood.

Table 1 lists maternal or neighborhood and child characteristics and overall n values in the first and the second columns, respectively; the corresponding mean plus or minus SD or n percentage values for Q1, Q2, Q3, and Q4 are listed in the other columns.

                                                                                Overall[^*a*^](#TF2){ref-type="table-fn"}   Quartiles of PFOA[^*b*^](#TF3){ref-type="table-fn"}                                           
  ----------------------------------------------------------------------------- ------------------------------------------- ----------------------------------------------------- ------------------- ------------------- -------------------
                                                                                $\text{Mean} \pm \text{SD}$ or *n* (%)                                                                                                    
  Maternal/neighborhood characteristics                                                                                                                                                                                   
   Maternal age at enrollment (y)                                               $31.8 \pm 5.7$                              $29.8 \pm 6.5$                                        $31.6 \pm 5.9$      $32.7 \pm 5.0$      $33.1 \pm 4.5$
   College graduate (%)                                                         364 (64)                                    59 (41)                                               89 (61)             101 (73)            115 (80)
   Individual household income (%)                                                                                                                                                                                        
    $< \$ 40,000$                                                               85 (16)                                     39 (30)                                               20 (14)             15 (11)             11 (8)
    $\$ 40,001–70,000$                                                          89 (16)                                     25 (19)                                               23 (17)             22 (16)             19 (13)
    $> \$ 70,000$                                                               369 (68)                                    65 (51)                                               96 (69)             98 (73)             110 (79)
   Census tract median household income (%)[^*c*^](#TF4){ref-type="table-fn"}                                                                                                                                             
    $< \$ 30,000$                                                               35 (6)                                      15 (11)                                               12 (8)              4 (3)               4 (3)
    $\$ 30,000–59,999$                                                          248 (44)                                    84 (59)                                               61 (42)             57 (41)             46 (32)
    $\$ 60,000–99,999$                                                          244 (43)                                    39 (27)                                               64 (44)             71 (51)             70 (49)
    $\geq \$ 100,000$                                                           43 (7)                                      4 (3)                                                 8 (6)               8 (6)               23 (16)
  Child characteristics                                                                                                                                                                                                   
   Age (y)                                                                      $7.9 \pm 0.8$                               $8.2 \pm 1.0$                                         $8.0 \pm 0.8$       $7.8 \pm 0.7$       $7.7 \pm 0.6$
   Female (%)                                                                   280 (49)                                    73 (50)                                               73 (50)             101 (45)            71 (49)
   Race/ethnicity (%)                                                                                                                                                                                                     
    White                                                                       328 (57)                                    37 (26)                                               80 (54)             94 (68)             117 (81)
    Black                                                                       129 (23)                                    66 (46)                                               32 (22)             21 (15)             10 (7)
    Asian                                                                       14 (2)                                      6 (4)                                                 2 (1)               2 (1)               4 (3)
    Hispanic                                                                    34 (6)                                      13 (9)                                                13 (9)              6 (4)               2 (1)
    Other                                                                       69 (12)                                     22 (15)                                               20 (14)             16 (12)             11 (8)
  Dairy intake (servings per week)                                              $2.2 \pm 1.5$                               $2.0 \pm 1.5$                                         $2.2 \pm 1.5$       $2.3 \pm 1.6$       $2.4 \pm 1.5$
  Physical activity (hours per week)                                            $1.9 \pm 1.4$                               $1.9 \pm 1.5$                                         $1.7 \pm 1.3$       $1.9 \pm 1.2$       $1.9 \pm 1.5$
   Year of blood draw (%)[^*c*^](#TF4){ref-type="table-fn"}                                                                                                                                                               
    2007                                                                        64 (11)                                     6 (4)                                                 17 (12)             16 (11)             25 (17)
    2008                                                                        203 (35)                                    21 (14)                                               39 (27)             62 (44)             81 (56)
    2009                                                                        189 (33)                                    56 (39)                                               58 (39)             45 (32)             30 (21)
    2010                                                                        120 (21)                                    62 (43)                                               33 (22)             17 (12)             8 (6)
    aBMD *z*-score                                                              $- 0.86 \pm 0.77$                           $- 0.73 \pm 0.73$                                     $- 0.81 \pm 0.84$   $- 0.95 \pm 0.73$   $- 0.93 \pm 0.78$
    BMC *z*-score                                                               $- 0.36 \pm 0.74$                           $- 0.24 \pm 0.70$                                     $- 0.37 \pm 0.84$   $- 0.42 \pm 0.69$   $- 0.44 \pm 0.70$

Note: aBMD, areal bone mineral density; BMC, bone mineral content; Q1, first/lowest quartile; SD, standard deviation.

Missing data for participants overall ($n = 576$): 4 missing maternal education, 6 census tract median household income, 33 individual household income, 2 race/ethnicity, 22 dairy intake, and 22 physical activity.

PFOA quartile minimum and maximum values: limit of detection $\left( \text{LOD} \right) < \, 0.1–3.0\text{ \ ng}/{mL}$ for Q1, $3.1–4.4\text{ \ ng}/{mL}$ for Q2, $4.5–6.1\text{ \ ng}/{mL}$ for Q3, and $6.2–14.3\text{ \ ng}/{mL}$ for Q4.

Percentages do not add up to 100% due to rounding.

Most PFASs considered in our study (except PFDA and MeFOSAA) were detectable in the plasma of $> 99\%$ of children. Plasma PFAS concentrations in our study were similar to those reported in U.S. children in the National Health and Nutrition Examination Survey (NHANES) during the same period, from 2007 to 2008 ([@c6]). The highest PFAS plasma concentrations in Project Viva were of PFOA \[median (IQR) $4.4\,\left( 3.2 \right)\text{ \ ng}/{mL}$\] and PFOS \[median (IQR) $6.4\,\left( 5.6 \right)\text{ \ ng}/{mL}$\]. PFAS plasma concentrations were moderately correlated \[Spearman's rank order correlation coefficient $\left( r_{s} \right) = 0.13–0.79$\], with the strongest correlations between PFOS and PFOA ($r_{s} = 0.79$) (see Table S3).

Single-Per- and Polyfluoroalkyl Substance Models {#s3.2}
------------------------------------------------

Children with higher plasma PFAS concentrations had lower aBMD *z*-scores in covariate-adjusted models ([Figure 1](#f1){ref-type="fig"}), with strongest associations for PFOA ($\beta$: $- 0.16$; 95% CI: $- 0.25$, $- 0.06$ per doubling of PFOA), PFOS ($\beta$ $- 0.08$; 95% CI $- 0.16$, $- 0.01$ per doubling of PFOS), and PFDA ($\beta$ $- 0.09$; 95% CI $- 0.16$, $- 0.02$ per doubling of PFDA). Each doubling of MeFOSAA was associated with 0.04 unit lower aBMD *z*-score \[95% confidence interval (CI): $- 0.08$, 0.01\], but CIs included the null. PFHxS and PFNA were not associated with aBMD *z*-score.

![Single-per- and polyfluoroalkyl substance (PFAS) models showing adjusted associations of individual PFAS plasma concentrations with areal bone mineral density (aBMD) *z*-score. Note: Adjusted for maternal age, education, census tract median household income, individual household income, and child age, sex, race/ethnicity, year of blood draw, dairy intake, and physical activity. $n = 531$ for all single-PFAS models. CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctanesulfonic acid; PFDA, perfluorodecanoate; PFHxS, perfluorohexane sulfonate; MeFOSAA, 2-(N-methyl-perfluorooctane sulfonamide) acetate; PFNA, perfluorononanoate.](ehp-127-087006-g0001){#f1}

Multi-Per- and Polyfluoroalkyl Substance Model {#s3.3}
----------------------------------------------

In the covariate-adjusted multi-PFAS model, each doubling of PFOA was associated a 0.24-unit-lower aBMD *z*-score (95% CI: $- 0.42$, $- 0.06$), whereas each doubling of PFNA was associated with a 0.12-unit-higher aBMD *z*-score (95% CI: 0.03, 0.21) ([Figure 2](#f2){ref-type="fig"}). Other PFASs were not associated with aBMD *z*-score.

![Multi-per- and polyfluoroalkyl substance (PFAS) model showing adjusted associations of PFAS plasma concentrations with areal bone mineral density (aBMD) *z*-score. Note: Adjusted for maternal age, education, census tract median household income, individual household income, and child age, sex, race/ethnicity, year of blood draw, dairy intake, and physical activity. $n = 531$. CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctanesulfonic acid; PFDA, perfluorodecanoate; PFHxS, perfluorohexane sulfonate; MeFOSAA - 2-(N-methyl-perfluorooctane sulfonamide) acetate; PFNA, perfluorononanoate.](ehp-127-087006-g0002){#f2}

Weighted Quantile Sum Regression Model {#s3.4}
--------------------------------------

The WQS index was negatively associated with aBMD *z*-score. Each IQR increment in the WQS index was associated with a $0.16$ lower aBMD *z*-score (95% CI: $- 0.28$, $- 0.04$). Within the mixture, PFDA had the highest weight (37%), followed by MeFOSAA (29%). As a result of their strong correlation with each other ($r_{s} = 0.79$), PFOA and PFOS had lower individual weights (23% and 8%, respectively). However, in combination, PFOS and PFOA contributed 31% of the total strength of the association between the PFAS mixture and aBMD *z*-score. Weights of PFHxS (3%) and PFNA (0%) were lower.

Sensitivity Analyses {#s3.5}
--------------------

When we adjusted single-PFAS models for maternal plasma concentrations of each PFAS in early pregnancy, associations between midchildhood plasma PFAS concentrations and aBMD *z*-score were slightly stronger. For example, among participants with data on maternal PFOA plasma concentration ($n = 423$), per doubling of PFOA, aBMD *z*-score was 0.18 units lower (95% CI: $- 0.28$, $- 0.07$) adjusting for maternal PFOA plasma concentration, vs. 0.16 units lower (95% CI: $- 0.25$, $- 0.06$) without adjustment (see Table S4).

The isomers of PFOA and PFOS we considered in this study had modestly stronger covariate-adjusted associations with aBMD *z*-score than their parent compounds. Areal BMD *z*-score was 0.23 units lower (95% CI: $- 0.37$, $- 0.09$) per doubling of n-PFOA vs. 0.16 units lower (95% CI: $- 0.25$, $- 0.06$) per doubling of total PFOA. Similarly, aBMD *z*-score was 0.12 units lower (95% CI: $- 0.22$, $- 0.01$) per doubling of n-PFOS and 0.12 units lower (95% CI: $- 0.23$, $- 0.01$) per doubling of Sm-PFOS vs. 0.08 units lower (95% CI: $- 0.16$, $- 0.01$) per doubling of total PFOS.

The directionality of associations between PFAS plasma concentrations and BMC *z*-score were similar to aBMD *z*-score in single-PFAS models, although CIs crossed the null for all PFAS--aBMC *z*-score associations (see Figure S2). For example, BMC *z*-score was 0.08 units lower (95% CI: $- 0.17$, 0.01), whereas aBMD *z*-score was 0.16 units lower (95% CI: $- 0.25$, $- 0.16$) per doubling of PFOA.

In single-PFAS models, no associations between plasma PFAS concentrations and aBMD *z*-score were modified by child sex (*p*-interaction terms were all $> 0.05$). However, we observed stronger associations of PFOA and PFDA plasma concentrations with aBMD *z*-score in girls as compared with boys in stratified analyses. In girls, aBMD *z*-score was 0.18 units lower (95% CI: $- 0.32$, $- 0.04$) per doubling of PFOA \[vs. 0.09 units lower (95% CI: $- 0.21$, 0.02) in boys, $p\text{-interaction} = 0.27$\] and 0.13 units lower (95% CI: $- 0.23$, $- 0.02$) per doubling of PFDA \[vs. 0.04 lower (95% CI: $- 0.13$, 0.05) in boys, $p\text{-interaction} = 0.28$\] (see Table S4).

Discussion {#s4}
==========

Our analysis of data from a large Boston-area cohort is among the first to investigate the role of an environmental exposure on bone mineral density in childhood. We found that children with greater plasma concentrations of select PFASs had lower aBMD *z*-scores during midchildhood.

Our findings align with our *a priori* hypothesis that higher PFAS exposure would be associated with lower BMD in childhood and are consistent with established biological pathways of action. For example, PFASs have been shown to activate $\text{PPAR}\gamma$ ([@c41]), which triggers mesenchymal stem cells to differentiate into adipocytes at the expense of osteoblasts and may thereby reduce BMD ([@c26]; [@c44]). PFASs also act as androgen receptor antagonists ([@c21]), which may further lower BMD ([@c7]). In addition, animal models suggest PFOS at environmentally relevant doses rapidly deposits into bone tissue ([@c2]). In a study of human bone bank and cadaver samples, PFOA and PFOS were sequestered in all femoral head samples and detected in bone marrow, with an association between higher bone PFOS concentration and lower bone volume, although this result was not statistically significant ([@c22]). Our findings substantiate existing evidence of biological pathways through which PFAS exposure may lower aBMD *z*-score.

Our research confirms and extends one relatively small study in children and two studies in older adults that found a cross-sectional association between greater PFAS plasma concentrations and lower BMD. In a pilot study of 48 obese children aged 8--12 y, greater plasma concentrations of PFOA, PFOS, PFNA, and PFHxS were associated with poorer bone health ([@c19]). However, this study was limited by a small sample size, limited statistical precision, and the use of calcaneal ultrasound bone measurements, which is not a standard bone assessment tool for use in children ([@c14]). Similarly, in 2,339 NHANES adults, greater PFOS but not PFOA was associated with lower lumbar spine BMD in premenopausal women but not postmenopausal women or men ([@c23]). In a different study of 1,914 NHANES adolescents and adults, higher serum PFOS concentrations were associated with lower femoral neck BMD in men, and higher serum PFOS and PFOA concentrations were associated with lower femur BMD in women ([@c18]). Thus, our finding of an association between greater PFAS plasma concentrations and lower BMD are in line with the limited existing epidemiologic literature.

To put our findings into perspective, the magnitude of the association between PFAS exposure and aBMD *z*-score in the present study \[0.16-unit-lower aBMD *z*-score (95% CI: $- 0.28$, $- 0.04$) per IQR increment in the WQS index\] was greater than that of other well-known determinants of aBMD evaluated in the Bone Mineral Density in Childhood Study ([@c48]). For example, spine aBMD *z*-score was 0.04 higher (95% CI: 0.02, 0.06) per additional hour per day of high-impact physical activity and $- 0.04$ lower (95% CI: $- 0.05$, $- 0.02$) per 1% increase in a BMD genetic risk score ([@c27]). Future studies of PFAS exposure and fracture incidence will help to elucidate the clinical relevance of these findings.

An advantage of our analysis was our ability to examine associations of several individual PFASs and the entire mixture with aBMD *z*-score. In single-PFAS models, we observed plasma concentrations of PFOA, PFOS, and PFDA to be most strongly associated with lower aBMD *z*-score. When we examined associations of individual PFASs independent of the other PFASs in a multi-PFAS model, only PFOA remained significantly associated with lower aBMD *z*-score. In our mixture model, we found the association between the PFAS mixture and lower aBMD *z*-score to be driven by PFDA. The different results may be due to high collinearity between PFOS and PFOA, as the mixture model accounts for collinearity between compounds, while the multi-PFAS model does not. It is important to note that PFDA plasma concentrations had relatively small variability in our cohort, with a range of $0.07–1.9\text{ \ ng}/{mL}$. Few epidemiologic studies have evaluated PFDA, and additional research would increase our understanding of the potential role of PFDA on aBMD and other health outcomes. Overall, our findings are in line with prior studies in our cohort that have shown PFOA, PFOS, and PFDA to have the strongest associations with other health outcomes, including insulin resistance ([@c12]), lipid profile ([@c28]), and visual--motor abilities ([@c16]).

Interestingly, in our multi-PFAS model, we found PFNA to be associated with higher (rather than lower) aBMD *z*-score. A similar inference may be made from the results of our WQS model, in which PFNA received a weight of zero in the composite weighted index, indicative of no (or negligible) negative association ([@c5]). This finding is consistent with the fact that PFNA activates $\text{PPAR}\alpha$ more strongly than the other PFASs ([@c41]; [@c42]), and $\text{PPAR}\alpha$ activation stimulates bone development and increases aBMD ([@c39]). Simultaneous activation of $\text{PPAR}\alpha$ and $\text{PPAR}\gamma$ may reduce the negative bone effects of $\text{PPAR}\gamma$ alone ([@c38]). The opposite direction of effect observed for PFNA in relation to aBMD *z*-score in our study, when compared with other PFAS, supports existing evidence of variation in mechanisms of action between PFASs and their consequent association with health outcomes.

We observed a stronger association of PFASs with aBMD in females than males, although these differences were not statistically significant. The direction and magnitude of our results are consistent with findings from the two prior adult NHANES analyses in which PFAS serum concentrations were associated with lower aBMD ([@c18]; [@c23]) and higher osteoporosis risk ([@c18]) in females relative to males. Rodent studies have also shown differences in the pharmacokinetic characteristics and tissue distribution of PFASs (specifically PFOA, PFOS, and PFHxS), with more rapid absorption in female as compared with male rats ([@c20]). Our study results align with these observations and strengthen the case for investigating sex-based differences in biological PFAS activity in humans.

As far as we are aware, our study is the largest data set to date to examine the association between childhood PFAS exposures (estimated from PFAS plasma concentrations) and aBMD, and the only pediatric study to evaluate total body (excluding skull) aBMD *z*-score using DXA, which is widely considered the gold standard for pediatric bone density measurements ([@c14]). A particular strength of this study was our evaluation of several PFASs and our ability to consider multiple potential confounding factors, including prenatal PFAS exposure. We were also able to account for determinants of bone mass, such as dairy intake and physical activity, although physical activity is challenging to quantify in children ([@c34]) and limited by questionnaire measures in this cohort. In addition, we used WQS regression, a novel statistical approach to address highly correlated mixtures of exposures. A limitation of our cross-sectional analysis is that we were not temporally positioned to assess for mediation by pubertal status or BMI, which have both been associated with PFAS plasma concentration ([@c25]; [@c11]) and aBMD ([@c33]; [@c9]). In addition, our sample size was not considered robust to splitting into training and validation data sets in the WQS analysis, and therefore, weights were estimated in the same data used to test for significance. Our results may have been influenced by multiple testing for associations between several PFAS and BMD, although consistent patterns in our results reduce this concern.

In summary, we are among the first to evaluate environmental exposures in relation to bone health in childhood. We observed higher exposure to PFASs to be associated with lower aBMD *z*-scores in children. While replication of our findings is necessary, lower exposures to environmental toxicants such as PFASs during childhood may improve childhood bone accrual and thereby optimize peak bone mass and lifelong skeletal health.
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